Century Therapeutics annual free cash flow
2020
2021
2022
2023
2024
2025
Century Therapeutics Free Cash Flow (FCF) History (IPSC)
Century Therapeutics reported −$104.7M in free cash flow for fiscal 2025, an increase of $5.6M from the previous fiscal year, with a free cash flow margin of −95.93%.
View full Century Therapeutics company overviewCentury Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$104.7M | $5.6M | — | −95.93% |
| 2024 | 2024-12-31 | −$110.3M | −$8.2M | — | −1673.84% |
| 2023 | 2023-12-31 | −$102.1M | −$85.5M | — | −4567.52% |
| 2022 | 2022-12-31 | −$16.6M | $117.4M | — | −318.37% |
| 2021 | 2021-12-31 | −$134.0M | −$82.9M | — | — |
| 2020 | 2020-12-31 | −$51.1M | — | — | — |
Century Therapeutics quarterly free cash flow
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$20.5M | $7.4M | — | — |
| Q1 2026 | 2026-03-31 | −$25.8M | $9.3M | — | — |
| Q4 2025 | 2025-12-31 | −$16.2M | $11.4M | — | — |
| Q3 2025 | 2025-09-30 | −$25.8M | $5.0M | — | — |
| Q2 2025 | 2025-06-30 | −$27.9M | −$699,000 | — | — |
| Q1 2025 | 2025-03-31 | −$35.1M | −$18.2M | — | −32.15% |
| Q2 2024 | 2024-06-30 | −$27.6M | −$3.8M | — | −3579.38% |
| Q1 2024 | 2024-03-31 | −$30.8M | $3.4M | — | −3600.82% |
| Q4 2023 | 2023-12-31 | −$27.2M | $2.0M | — | −10152.99% |
| Q3 2023 | 2023-09-30 | −$16.9M | $17.1M | — | −11428.38% |
| Q2 2023 | 2023-06-30 | −$23.8M | $12.3M | — | −23989.90% |
| Q1 2023 | 2023-03-31 | −$34.2M | −$116.9M | — | −1988.95% |
| Q4 2022 | 2022-12-31 | −$29.2M | $11.9M | — | −5599.81% |
| Q3 2022 | 2022-09-30 | −$34.0M | $5.7M | — | −1531.03% |
| Q2 2022 | 2022-06-30 | −$36.0M | −$6.9M | — | −2579.73% |
| Q1 2022 | 2022-03-31 | $82.7M | $106.7M | — | +7815.31% |
| Q4 2021 | 2021-12-31 | −$41.1M | −$27.3M | — | — |
| Q3 2021 | 2021-09-30 | −$39.7M | — | — | — |
| Q2 2021 | 2021-06-30 | −$29.1M | — | — | — |
| Q1 2021 | 2021-03-31 | −$24.1M | — | — | — |
| Q3 2020 | 2020-09-30 | −$13.7M | — | — | — |
Century Therapeutics free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$51.1M to −$104.7M, a net decrease of $53.6M. Century Therapeutics's latest reported quarter, Q2 2026, generated −$20.5M in free cash flow, an increase of $7.4M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Century Therapeutics filings at SEC.gov ↗